Viking Therapeutics reported that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, with no patients experiencing BMI worsening. The Phase 2 VENTURE trial also showed significant improvements in waist circumference, blood pressure, cholesterol, glucose, and insulin levels among those with BMI improvement. VK2735, a dual GLP-1/GIP receptor agonist, demonstrated progressive weight loss up to 14.7% and was well tolerated. Viking is now conducting Phase 3 VANQUISH trials to further evaluate VK2735's long-term efficacy and safety in obesity and type 2 diabetes, expected to complete in 2027.
Viking Therapeutics' obesity drug VK2735 is highlighted amid a Health-sector market where 71 of 150 US stocks rose and 77 fell on Pluang. Notable movers include Abeona Therapeutics Inc (ABEO) with a 5.68% gain and 100% buy order activity, Alnylam Pharmaceuticals (ALNY) up 5.36%, and Aveanna Healthcare Holdings (AVAH) down 6.05%. This snapshot is as of Nov 16, 2026 00:01 WIB.
In Q3 2026, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index, driven by strong holdings in Information Technology, Financials, and Consumer Staples sectors. The fund's success was attributed to company-specific fundam...
The Schwab US Dividend Equity ETF (SCHD) has rallied about 10% since early October, supported by stronger earnings from key holdings like Texas Instruments and UnitedHealth, as well as inflows into dividend-focused funds. SCHD trades at roughly 18.6 ...
Helus Pharma will present topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disorder on November 16, 2026. This drug has received Breakthrough Therapy Designation from the FDA, highlight...
Eaton Vance Tax-Advantaged Global Dividend Income Fund (ETG) raised its monthly distribution by 23.7%, marking its highest payout since inception. Despite this increase and strong long-term returns, ETG shares trade at a significant discount of over ...
U.S. Treasury Secretary Scott Bessent called for a major overhaul at Nvidia following CEO Jensen Huang's resignation amid allegations of illicit chip sales to China. Bessent urged the company to hire an external CEO and suggested scrutiny of other ex...
